Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21312283 | 0.89 | OPRM1 (0.58) | OPRM1OPRL1OPRK1DRD4POLB | |
| SCHEMBL1822928 | 0.83 | OPRM1 (0.74) | OPRM1OPRL1OPRK1SLC6A4 | |
| SCHEMBL27796288 | 0.81 | OPRM1 (0.38) | OPRM1OPRL1OPRK1 | |
| SCHEMBL3155723 | 0.81 | OPRM1 (0.53) | OPRM1OPRL1OPRK1 | |
| SCHEMBL16463053 | 0.81 | OPRM1 (0.53) | OPRM1OPRL1OPRK1SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL28226628 | 0.81 | OPRM1 (0.71) | OPRM1OPRL1OPRK1SLC6A4 | |
| SCHEMBL24855493 | 0.81 | OPRM1 (0.51) | OPRM1OPRL1OPRK1 | |
| SCHEMBL28872330 | 0.80 | OPRM1 (0.47) | OPRM1OPRK1DRD4OPRD1SLC22A1 | |
| SCHEMBL294583 | 0.79 | OPRM1 (0.63) | OPRM1OPRL1OPRK1SLC6A4 | |
| SCHEMBL294971 | 0.79 | OPRM1 (0.63) | OPRM1OPRL1OPRK1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101679406-B | Thiazolyl compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2013-07-10 | — | — | CN | disclosed |
| CN-101679406-A | Thiazolyl compounds useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2010-03-24 | — | — | CN | disclosed |
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | OPRM1 124/4885OPRL1 58/4885OPRK1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.